Latest news

27 Oct 2020
Idorsia announces financial results for the first nine months of 2020
21 Oct 2020
Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million
20 Oct 2020
Idorsia announces the results of its rights offering in the context of the capital increase
08 Oct 2020
Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline
02 Sep 2020
Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
02 Sep 2020
Idorsia assigns and transfers agreement with ReveraGen to Santhera
31 Aug 2020
Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States
28 Aug 2020
Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
13 Aug 2020
Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020
06 Aug 2020
Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing
23 Jul 2020
Idorsia announces financial results for the first half 2020
16 Jul 2020
Idorsia establishes US commercial operations and leadership team
06 Jul 2020
Idorsia announces positive results in the second Phase 3 study of daridorexant
20 May 2020
Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan
19 May 2020
Idorsia launches an offering of new shares to fund the company’s growth plan
13 May 2020
Idorsia holds its third Annual General Meeting of Shareholders
12 May 2020
Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy
23 Apr 2020
Idorsia announces financial results for the first quarter 2020
20 Apr 2020
Idorsia announces positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia
02 Apr 2020
Idorsia issues Notice of the 2020 Annual General Meeting of Shareholders